Original Articles
Correlation of glycemic control with dyslipidemia, atherogenicity, c reactive protein and microalbuminuria in type 2 diabetes patients | |
Pankaj Sharma, Dr. Sherya Nigosker, Dr. Jyoti Dave | |
Background: Diabetes mellitus, characterized by persistent hyperglycemia due to insulin resistance or deficiency, is rapidly increasing in prevalence, with projections estimating 438 million cases by 2030. The rising incidence, especially of type 2 diabetes, is associated with obesity, sedentary lifestyles, and an aging population. This study investigates correlations between glycemic control, dyslipidemia, C-reactive protein (CRP), and microalbuminuria in patients with type 2 diabetes. Aim: This study aims to correlate glycemic control, assessed by glycated hemoglobin (HbA1c), with dyslipidemia, atherogenicity, CRP levels, and microalbuminuria in individuals with type 2 diabetes mellitus. Methodology: A cross-sectional study was conducted involving 200 patients with type 2 diabetes, recruited from outpatient and inpatient settings at Index Medical College, Hospital and research centre, Indore, Participants underwent comprehensive clinical examinations, with glycemic control evaluated through HbA1c measured via high-performance liquid chromatography. Lipid profiles, including triglycerides, total cholesterol, HDL, and LDL, were analyzed enzymatically. The atherogenic index of plasma (AIP) was calculated, CRP levels were assessed using latex agglutination, and urinary albumin excretion was measured to determine microalbuminuria. Results: The analysis revealed significant differences in total cholesterol, triglycerides, LDL, HDL levels, AIP, CRP, and urinary albumin excretion between patients with HbA1c <7% and >7%. These findings highlight strong correlations with cardiovascular risk and nephropathy, suggesting that poor glycemic control is associated with adverse lipid profiles and inflammatory markers. Conclusion: HbA1c not only serves as a vital marker for glycemic control but also as an important biomarker for evaluating atherogenic dyslipidemia, cardiovascular risk, and early nephropathy in patients with type 2 diabetes, emphasizing the need for regular monitoring and management strategies to mitigate complications. |
|
Abstract View | Download PDF | Current Issue |
IJLBPR
322 Parlount Road Slough Berkshire SL3 8AX, UK
ijlbpr@gmail.com
© IJLBPR. All Rights Reserved.